Introduction
Nosocomial (Blood stream infections) BSIs are growing problems in tertiary care hospitals throughout the world. Bacteria have been the traditional etiology of nosocomial BSIs, but with increasing use of broad spectrum antibiotics, central venous catheters (CVC) and indwelling devices, fungi have superseded bacteria. [1] Among fungi, Candida spp. is the commonest and is the fourth most common cause of BSI in hospitalised patients. [2] Candida spp. possesses a number of virulence factors including biofi lm production. Biofi lms are the structured microbial communities that are attached and encased in a matrix of exopolymeric material. [3] Candida spp. has the ability to form extensive biofi lm on catheters and other prosthetic devices which contributes to its prevalence as an etiologic agent of intravascular nosocomial infections. Central venous catheters are considered as the most Bhatt, et al.: Biofi lm by Candida from nosocomial fungemia S113 February 24 hours and 48 hours, respectively, after which the broth was aspirated out and stained with safranin. In tubes, biofi lm production was observed visually by two separate observers and correlated. Biofi lm formation was considered positive when a visible fi lm lined the walls and bottoms of the tubes but ring formation at the liquid interface was not considered. The absorbance of the microtitre wells were measured at wavelength 630 nm by Micro ELISA auto reader. A blank well with reagent was also measured for absorbance [% of transmittance (%t) blank]. The %t was substracted from %t blank to obtain the amount of light blocked. Biofi lm production was scored as negative, 1+, 2+, 3+ and 4+ when %t blank = <5, 5-20, 20-35 and >50, respectively. Experiment was performed in triplicate and the data was then averaged.
All the isolates were subjected to antifungal susceptibility testing by microbroth dilution technique using amphotericin B, voriconazole, fl uconazole, itraconazole and 5-fl ucytocine as per CLSI M-27-A2,2002. [9] Inoculum was prepared using Roswell Park Memorial Institute 1,640 medium with glutamin phenol red and 0.2% glucose at PH 7 and standardised to 0.5 Mc Farland. Antifungal powders were procured from commercial sources and stock solutions were made with DMSO and tested in serial dilution for each antifungal with different concentrations. Tests were interpreted after 24 hours incubation at 37 0 c by visual method with reading mirror and compared with controls (C. albicans ATCC 90028 and C. parapsilosis ATCC 95142).
Results
A total of 34 (9.4%) Candida spp. were isolated among which 13 (39%) were C. tropicalis, 7 (20%) C parapsilosis, 5 (14.7%) each of C. kruseiand C. Albicans and 2 (5.4%) were C. glabrata. Two isolates could not be identifi ed up to species and were not subjected to biofi lm production [ Table 1 ]. Among the 32 isolates subjected for biofi lm production, 22 (64.7%) were positive along with the standard strains. No major discrepancies were observed between visual and spectrophotometric reading. Strong biofi lm production (3+, 2+) was seen in 13 strains and weak (1+) in 9 strains. C. parapsilosis and C. tropicalis were found to be strong biofi lm producers whereas C. Albicans and C. krusei were identifi ed as weak producers. Antifungal susceptibility showed 5-Flucytocine to be the most resistant drug followed by fl uconazole. Amphotericin B was found as the most susceptible antifungal agent [ Figure 1 -2].
Discussion
Blood stream infections by fungi were prevalent since long but the incidence of nosocomial candidemia has increased dramatically over the last 2 decades. [10] Approximately, 200 Candida spp are known, but only 10% are recognised as human pathogens and C. albicans was the single most common species causing nosocomial BSI so far. Recent reports suggest a shift towards non-albicans Candida spp. like C. tropicalis and C. parasilosis. [11, 12] The prevalence of nosocomial candidemia in the present study was found to be 9.4% which correlates approximately with that of Xess et al., (6%) from All India Institutes of Medical Sciences (AIIMS) and Sahni et al., (6.9%) from Maulana Azad Medical College (MAMC) New Delhi. [1, 10] Risk factors for candidaemia are increasingly associated with ICU patients as being subjected to invasive procedures, IV catheterisation and hyperelimentation. [10, 13] In the present study 100% [11, 14] The exact cause for this could not be explained however increased use of fl uconazole could be the major contributing factor. [12] Moreover, C. parapsilosis is found commonly on skin surface and has better adherence to materials like acrylic, glucose and parenteral nutrition solutions which is considered very similar to the concentration in milieuinterior. [4] Hence the detection of C. parapsilosis in BSI is an indication of exogenous infection. [12] Biofi lm production was detected in 64.7% of the isolates in this study among which non-albicans Candida spp. (C. tropicalis and C. parapsilosis) were strong producers. Another study had similar fi ndings of non-albicans Candida as strong biofi lm producer but their overall rate of biofi lm production was higher in comparison to ours. [8] The antifungal susceptibility results showed highest resistance to 5 Flucytosine and Fluconazole (37% and 35%, respectively) although Voriconazole, Itraconazole and Amp-B showed good effi cacy. Western studies reported Candida spp. to be remarkably susceptible to Polyenes, Flucytosine, Azoles and Echinocandins. [15] But an Indian study had reported very high resistance toVoriconazole (56%) and Fluconazole (36%) although Amp-B susceptibility was as high (92%) as ours. [14] We observed higher degree of resistance to Fluconazole in biofi lm producers as compared to non-producers as reported by several authors. [5] Possible resistance mechanism involves restricted penetration of drug through biofi lm matrix, phenotypic changes resulting from a decreased growth and nutritional limitation, expression of resistance genes induced by contact with a surface and persistence of a small number of cells.
Conclusion
To conclude, non-albicans candidaemia is on rise and biofi lm production is responsible for increasing antifungal resistance. The changing epidemiology of candidaemia, therefore, highlights the need for close monitoring on the distribution, susceptibility and biofi lm production of Candida spp. in order to optimise therapy and outcome.
